Eloxx Pharmaceuticals Inc (ELOX) FinancialsELOXEloxx Pharmaceuticals Inc

In the context of the broader market, ELOX competes directly with industry leaders such as IMA and HRTX. With a market capitalization of $64.58M, it holds a significant position in the sector. When comparing efficiency, ELOX's gross margin of N/A stands against IMA's N/A and HRTX's 69.28%. Such benchmarking helps identify whether Eloxx Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Eloxx has shown a significant increase in losses, with a net income loss of $4.5 million in Q2 2026, compared to $1.9 million in the same quarter last year. Despite this, the company's total equity improved to $46.42 million in Q2 2026, indicating a stronger balance sheet.